The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).
 
John V. Reynolds
No Relationships to Disclose
 
Shaun R. Preston
Travel, Accommodations, Expenses - Intuitive Surgical
 
Brian O'Neill
Travel, Accommodations, Expenses - Ipsen
 
Maeve Aine Lowery
Consulting or Advisory Role - Agios; Roche/Genentech
Travel, Accommodations, Expenses - Ipsen
 
Lene Baeksgaard
No Relationships to Disclose
 
Thomas Crosby
Honoraria - Bristol-Myers Squibb; Celgene; Janssen; MSD; Roche; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; MSD; Roche; SERVIER
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Janssen; MSD; Roche; SERVIER
 
Moya Cunningham
Honoraria - Baxter (I); Bayer (I); Bristol-Myers Squibb (I); Leo Pharma (I); Novo Nordisk (I); Octapharm (I); Pfizer (I); Roche (I); Shire (I); SOBI (I); Takeda (I)
Consulting or Advisory Role - Baxter (I); Bayer (I); Bristol-Myers Squibb (I); CSL Behring (I); Daiichi Sankyo (I); Octapharm (I); Pfizer (I); Shire (I); SOBI (I); Takeda (I)
Speakers' Bureau - Baxter (I); Bayer (I); Bristol-Myers Squibb (I); Leo Pharma (I); Novo Nordisk (I); Octapharm (I); Pfizer (I); Roche (I); Shire (I); SOBI (I); Takeda (I)
Research Funding - 3M (I); Baxalta (I); Baxter (I); Bayer (I); Novo Nordisk (I); Pfizer (I); Shire (I); Takeda (I)
 
Sinead Cuffe
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche
 
Gareth Owen Griffiths
Honoraria - AstraZeneca
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BionTEch (Inst); Bristol-Myers Squibb (Inst); Heartflow (Inst); Jannsenn-Cilag (Inst); Novartis (Inst); Roche (Inst)
 
Rajarshi Roy
Honoraria - Amgen; Merck; SERVIER
Consulting or Advisory Role - SERVIER
Speakers' Bureau - Merck; SERVIER
Travel, Accommodations, Expenses - Merck; SERVIER
 
Stephen Falk
Stock and Other Ownership Interests - GlaxoSmithKline
Consulting or Advisory Role - BMS
Speakers' Bureau - Amgen; Merck Serono; Merck Serono; Merck Serono; SERVIER
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Celgene
Other Relationship - SERVIER
 
George Hanna
No Relationships to Disclose
 
Frederick R. Bartlett
No Relationships to Disclose
 
Imelda Parker
No Relationships to Disclose
 
Alberto Alvarez-Iglesias
No Relationships to Disclose
 
Magnus Nilsson
Travel, Accommodations, Expenses - Medtronic
 
Guillaume Piessen
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Nestle health science; Roche; Stryker
Travel, Accommodations, Expenses - medtronic
(OPTIONAL) Uncompensated Relationships - Medtronic
 
Signe Risum
No Relationships to Disclose
 
Narayanasamy Ravi
No Relationships to Disclose
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche